SCHEMBL2156325 — predicted protein targets

Predicted protein targets (top 19)

	gene	UniProt	supporting neighbours	confidence
▸	USP5	P45974	1/20	0.37

▸	CCR5	P51681	1/20	0.36

▸	DPP4	P27487	1/20	0.33

▸	DPP8	Q6V1X1	1/20	0.33

▸	DPP9	Q86TI2	1/20	0.33

▸	DPP7	Q9UHL4	1/20	0.33

▸	CCR2	P41597	4/20	0.33

▸	HTR7	P34969	1/20	0.33

▸	DRD2	P14416	4/20	0.33

▸	HTR1A	P08908	2/20	0.33

▸	HTR2A	P28223	2/20	0.33

▸	DRD3	P35462	2/20	0.33

▸	NAMPT	P43490	1/20	0.32

▸	LMNA	P02545	1/20	0.32

▸	SMN1; SMN2	Q16637	1/20	0.32

▸	DRD1	P21728	1/20	0.32

▸	DRD5	P21918	1/20	0.32

▸	SPHK1	Q9NYA1	1/20	0.32

▸	COMT	P21964	1/20	0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL2156322	1.00	USP5 (0.37)	USP5CCR5DPP4DPP8DPP9
SCHEMBL2156588	0.90	USP2 (0.38)	USP5CCR5DRD2DRD3LMNA
SCHEMBL2156585	0.90	USP2 (0.38)	USP5CCR5DRD2DRD3LMNA
SCHEMBL2155509	0.89	DRD2 (0.44)	USP5CCR2DRD2LMNA
SCHEMBL2155511	0.89	DRD2 (0.44)	USP5CCR2DRD2LMNA
SCHEMBL2155404	0.88	DRD2 (0.46)	USP5CCR2DRD2SMN1; SMN2
SCHEMBL2155400	0.88	DRD2 (0.46)	USP5CCR2DRD2SMN1; SMN2
SCHEMBL2155132	0.83	MEN1 (0.50)	LMNA
SCHEMBL2155128	0.83	MEN1 (0.50)	LMNA
SCHEMBL2156980	0.83	MEN1 (0.50)	LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-1828160-B1	SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS	MERCK SERONO SA (CH)	2011-12-14	—	—	EP	claimed
US-20080194520-A1	Sulfonyl Amino Cyclic Derivatives and Use Thereof	MERCK SERONO SA (CH)	2008-08-14	—	—	US	claimed
CN-101124213-A	Sulfonylamino cyclic derivatives and uses thereof	SERONO LAB (CH)	2008-02-13	—	—	CN	claimed
EP-1828160-A1	SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS	LABORATOIRES SERONO S.A. (CH)	2007-09-05	—	—	EP	claimed
WO-2006067114-A1	SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF	LABORATOIRES SERONO S.A. (CH)	2006-06-29	—	—	WO	claimed
US-7973039-B2	3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors	MERCK SERONO SA (CH)	2011-07-05	—	—	US	disclosed
US-20080194520-A1	Sulfonyl Amino Cyclic Derivatives and Use Thereof	MERCK SERONO SA (CH)	2008-08-14	—	—	US	disclosed
CN-101124213-A	Sulfonylamino cyclic derivatives and uses thereof	SERONO LAB (CH)	2008-02-13	—	—	CN	disclosed
EP-1828160-A1	SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS	LABORATOIRES SERONO S.A. (CH)	2007-09-05	—	—	EP	disclosed
WO-2006067114-A1	SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF	LABORATOIRES SERONO S.A. (CH)	2006-06-29	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20080194520-A1	Sulfonyl Amino Cyclic Derivatives and Use Thereof	GLS2, SRM, GLS	USP5 1355/4885CCR5 1642/4885DPP4 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.